asa statement on glp 1 Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis ASA Advises No Longer Holding – Perioperative management of patients taking

GLP-1 Receptor Agonist Use and Risk of Suicide Death

Hydration and Salt Intake Spironolactone increases urinary sodium excretion

[Many people tend to regain weight once they stop using the drugs.] SN : What do you want people considering taking GLP-1 drugs to know

If you didnt know, serotonin levels help influence deep sleep and wakefulness

According to a recent study by SNS Insider, the global GLP-1 Receptor Agonist Market size valued at USD 60.6 billion in 2025, is anticipated to grow to USD 307 billion by 2035, registering a CAGR of 17.61% over the 20262035 forecast period. The increasing clinician acceptability of GLP-1 receptor agonists, the commercial success of blockbusters such as Ozempic and Wegovy, and new drug development are changing the face of diabetes and obesity treatment around the world